Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Social Psychiatry and Psychiatric Epidemiology
Erschienen in:

27.02.2024 | Research

Employing Bayesian analysis to establish a cut-off point and assess stigma prevalence in substance use disorder: a comprehensive study of the Chinese version of the Substance Use Stigma Mechanism Scale

verfasst von: Dongfang Wang, Yanan Zhou, Shubao Chen, Qiuxia Wu, Li He, Qianjin Wang, Yuzhu Hao, Yueheng Liu, Pu Peng, Manyun Li, Tieqiao Liu, Yuejiao Ma

Erschienen in: Social Psychiatry and Psychiatric Epidemiology | Ausgabe 10/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In China, individuals with substance use disorders (SUD) face severe stigma, but reliable stigma assessment tool is lacking. Therefore, this study aimed to validate the Chinese version of the Substance Use Stigma Mechanism Scale (SU-SMS-C) and set its cut-off point.

Methods

We recruited 1005 individuals with SUDs from Chinese rehabilitation centers. These participants completed a battery of questionnaires that included the SU-SMS-C, The Multidimensional Scale of Perceived Social Support (MSPSS), Center for Epidemiologic Studies Depression Scale (CES-D), General Self-Efficacy Scale (GSES), and Perceived Devaluation and Discrimination (PDD). Confirmatory factor analysis was used to assess the construct validity of the scale. Additionally, the Naive Bayes classifier was used to establish the cut-off point for the SU-SMS-C. We additionally explored the correlation between patient demographic characteristics and stigma.

Results

A confirmatory factor analysis was utilized, revealing a second-order five-factor model. Based on the Naive Bayes classifier, the area under the receiver operating characteristic (AUCROC) of 0.746, the cut-off point for the SU-SMS-C was established at 44.5. The prevalence of stigma observed in the study population was 49.05%. Significant disparities were observed in the distribution of stigma across genders, with males experiencing more pronounced stigma than females. Moreover, patients consuming different primary substances reported diverse levels of stigma. Notably, those primarily using heroin endured a higher degree of stigma than users of other substances.

Conclusion

The study is the first to identify a cut-off point for the SU-SMS-C by Naive Bayes classifier, bridging a major gap in stigma measurement research. SU-SMS-C may help treat and manage SUDs by reducing stigma.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Lord S, Moore SK, Ramsey A, Dinauer S, Johnson K (2016) Implementation of a substance use recovery support mobile phone app in community settings: qualitative study of clinician and staff perspectives of facilitators and barriers. JMIR Ment Health 3(2):e4927CrossRef
2.
Wang Z, Li W-x, Zhi-Min L (2017) Similarity and difference in drug addiction process between heroin-and methamphetamine-dependent users. Subst Use Misuse 52(4):459–467PubMedCrossRef
3.
Drugs UNOo, Crime (2019) World Drug Report 2019: stimulants, Booklet 4. United Nations publication, New York (NY)
4.
Manning V, Garfield JB, Best D, Berends L, Room R, Mugavin J, Larner A, Lam T, Buykx P, Allsop S (2017) Substance use outcomes following treatment: findings from the Australian patient pathways study. Aust N Z J Psychiatry 51(2):177–189PubMedCrossRef
5.
Rhee TG, Rosenheck RA (2019) Use of drug treatment services among adults with opioid use disorder: rates, patterns, and correlates. Psychiatr Serv 70(11):992–999PubMedCrossRef
6.
Office UN, Drugs o, Crime (2018) World Drug Report 2018 (Sales No. E. 18. XI. 9)
7.
Blanco C, Iza M, Rodríguez-Fernández JM, Baca-García E, Wang S, Olfson M (2015) Probability and predictors of treatment-seeking for substance use disorders in the US. Drug Alcohol Depend 149:136–144PubMedPubMedCentralCrossRef
8.
Mak WW, Chan RC, Wong SY, Lau JT, Tang WK, Tang AK, Chiang TP, Cheng SK, Chan F, Cheung FM (2017) A cross-diagnostic investigation of the differential impact of discrimination on clinical and personal recovery. Psychiatr Serv 68(2):159–166PubMedCrossRef
9.
Grønnestad TE, Sagvaag H (2016) Stuck in limbo: illicit drug users’ experiences with opioid maintenance treatment and the relation to recovery. Int J Qual Stud Health Well Being 11(1):31992PubMedCrossRef
10.
McCallum SL, Mikocka-Walus AA, Gaughwin MD, Andrews JM, Turnbull DA (2016) ‘I’m a sick person, not a bad person’: patient experiences of treatments for alcohol use disorders. Health Expect 19(4):828–841PubMedCrossRef
11.
Pauly BB, Gray E, Perkin K, Chow C, Vallance K, Krysowaty B, Stockwell T (2016) Finding safety: a pilot study of managed alcohol program participants’ perceptions of housing and quality of life. Harm Reduct J 13(1):15PubMedCrossRef
12.
Melchior H, Hüsing P, Grundmann J, Lotzin A, Hiller P, Pan Y, Driessen M, Scherbaum N, Schneider B, Hillemacher T (2019) Substance abuse-related self-stigma in women with substance use disorder and comorbid posttraumatic stress disorder. Eur Addict Res 25(1):20–29PubMedCrossRef
13.
Chang CW, Chang KC, Griffiths MD, Chang CC, Lin CY, Pakpour AH (2022) The mediating role of perceived social support in the relationship between perceived stigma and depression among individuals diagnosed with substance use disorders. J Psychiatr Ment Health Nurs 29(2):307–316PubMedCrossRef
14.
Brown SA, Kramer K, Lewno B, Dumas L, Sacchetti G, Powell E (2015) Correlates of self-stigma among individuals with substance use problems. Int J Ment Heal Addict 13:687–698CrossRef
15.
Luoma JB, Nobles RH, Drake CE, Hayes SC, O’Hair A, Fletcher L, Kohlenberg BS (2013) Self-stigma in substance abuse: development of a new measure. J Psychopathol Behav Assess 35(2):223–234PubMedCrossRef
16.
Rüsch N, Angermeyer MC, Corrigan PW (2005) Mental illness stigma: concepts, consequences, and initiatives to reduce stigma. Eur Psychiatry 20(8):529–539PubMedCrossRef
17.
Luoma JB, O’Hair AK, Kohlenberg BS, Hayes SC, Fletcher L (2010) The development and psychometric properties of a new measure of perceived stigma toward substance users. Subst Use Misuse 45(1–2):47–57PubMedPubMedCentralCrossRef
18.
Van Boekel LC, Brouwers EP, Van Weeghel J, Garretsen HF (2013) Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review. Drug Alcohol Depend 131(1–2):23–35PubMedCrossRef
19.
Brohan E, Slade M, Clement S, Thornicroft G (2010) Experiences of mental illness stigma, prejudice and discrimination: a review of measures. BMC Health Serv Res 10(1):80PubMedPubMedCentralCrossRef
20.
Smith LR, Earnshaw VA, Copenhaver MM, Cunningham CO (2016) Substance use stigma: reliability and validity of a theory-based scale for substance-using populations. Drug Alcohol Depend 162:34–43PubMedPubMedCentralCrossRef
21.
Earnshaw V, Smith L, Copenhaver M (2013) Drug addiction stigma in the context of methadone maintenance therapy: an investigation into understudied sources of stigma. Int J Ment Heal Addict 11(1):110–122CrossRef
22.
23.
Link BG, Struening EL, Rahav M, Phelan JC, Nuttbrock L (1997) On stigma and its consequences: evidence from a longitudinal study of men with dual diagnoses of mental illness and substance abuse. J Health Soc Behav 38(2):177–190PubMedCrossRef
24.
Earnshaw V, Smith L, Copenhaver M (2013) Drug addiction stigma in the context of methadone maintenance therapy: an investigation into understudied sources of stigma. Int J Ment Heal Addict 11:110–122CrossRef
25.
Link BG, Yang LH, Phelan JC, Collins PY (2004) Measuring mental illness stigma. Schizophr Bull 30(3):511–541PubMedCrossRef
26.
Ahern J, Stuber J, Galea S (2007) Stigma, discrimination and the health of illicit drug users. Drug Alcohol Depend 88(2–3):188–196PubMedCrossRef
27.
Keyes KM, Hatzenbuehler ML, McLaughlin KA, Link B, Olfson M, Grant B, Hasin D (2010) Stigma and treatment for alcohol disorders in the United States. Am J Epidemiol 172(12):1364–1372PubMedPubMedCentralCrossRef
28.
Varas-Díaz N, Negrón SS, Neilands TB, Bou FC, Rivera SM (2010) Stigmatization of illicit drug use among Puerto Rican health professionals in training. P R Health Sci J 29(2):109PubMedPubMedCentral
29.
Latkin C, Srikrishnan AK, Yang C, Johnson S, Solomon SS, Kumar S, Celentano DD, Solomon S (2010) The relationship between drug use stigma and HIV injection risk behaviors among injection drug users in Chennai, India. Drug Alcohol Depend 110(3):221–227PubMedPubMedCentralCrossRef
30.
Palamar JJ, Kiang MV, Halkitis PN (2012) Predictors of stigmatization towards use of various illicit drugs among emerging adults. J Psychoact Drugs 44(3):243–251CrossRef
31.
Luoma JB, Nobles RH, Drake CE, Hayes SC, O’Hair A, Fletcher L, Kohlenberg BS (2013) Self-stigma in substance abuse: development of a new measure. J Psychopathol Behav Assess 35:223–234PubMedCrossRef
32.
Can Gür G, Tanriverdi D, Ariti M, Özgün Öztürk F (2022) The adaptation of the substance use stigma mechanism scale (SU-SMS) into Turkish: a validity and reliability study. J Am Psychiatr Nurses Assoc 28(4):295–305PubMedCrossRef
33.
Rafful C, López A, Contreras-Valdez JA, Morales M, Jiménez-Rivagorza L, Orozco R (2022) Substance use stigma mechanisms scale: factor structure, reliability, and validity in Mexican adults that use drugs. Drug Alcohol Depend 239:109598PubMedCrossRef
34.
Chou K-L (2000) Assessing Chinese adolescents’ social support: the multidimensional scale of perceived social support. Personality Individ Differ 28(2):299–307CrossRef
35.
Zhou K, Li H, Wei X, Yin J, Liang P, Zhang H, Kou L, Hao M, You L, Li X (2015) Reliability and validity of the multidimensional scale of perceived social support in Chinese mainland patients with methadone maintenance treatment. Compr Psychiatry 60:182–188PubMedCrossRef
36.
Wang D, Zhu F, Xi S, Niu L, Tebes JK, Xiao S, Yu Y (2021) Psychometric properties of the multidimensional scale of perceived social support (MSPSS) among family caregivers of people with schizophrenia in China. Psychol Res Behav Manag 14:1201–1209PubMedPubMedCentralCrossRef
37.
38.
Akdağ EM, Kotan VO, Kose S, Tıkır B, Aydemir MÇ, Okay İT, Göka E, Özkaya G (2018) The relationship between internalized stigma and treatment motivation, perceived social support, depression and anxiety levels in opioid use disorder. Psychiatry Clin Psychopharmacol 28(4):394–401CrossRef
39.
Wang Z-Y, Liu L, Shi M, Wang L (2016) Exploring correlations between positive psychological resources and symptoms of psychological distress among hematological cancer patients: a cross-sectional study. Psychol Health Med 21(5):571–582PubMedCrossRef
40.
Chiu FP, Tsang HW (2004) Validation of the Chinese general self-efficacy scale among individuals with schizophrenia in Hong Kong. Int J Rehabil Res 27(2):159–161PubMedCrossRef
41.
Wang C, Liu Y (2000) Correlation among general self-efficacy, trait anxiety, state anxiety and test anxiety. Chinese Journal of Clinical Psychology (04)
42.
Link BG, Struening EL, Neese-Todd S, Asmussen S, Phelan JC (2001) Stigma as a barrier to recovery: the consequences of stigma for the self-esteem of people with mental illnesses. Psychiatr Serv 52(12):1621–1626PubMedCrossRef
43.
Li J, Zhang M-m, Zhao L, Li W-q, Mu J-l, Zhang Z-h (2018) Evaluation of attitudes and knowledge toward mental disorders in a sample of the Chinese population using a web-based approach. BMC Psychiatry 18(1):1–8CrossRef
44.
Marcoulides GA, Leite WL (2013) Exploratory data mining algorithms for conducting searches in structural equation modeling. Contemporary issues in exploratory data mining in the behavioral sciences, pp 150–171
45.
McCallum A, Nigam KA (1998) Comparison of event models for naive bayes text classification. In: AAAI-98 workshop on learning for text categorization, vol. 1. Madison, WI, pp 41–48
46.
Hosmer D, Lemeshow S (2000) Applied logistic regression. A Wiley-Interscience publication. Wiley, New York, Chichester. Weinheim, Brisbane, Singapore, Toronto
47.
Hard ML, Mills RJ, Sadler BM, Turncliff RZ, Citrome L (2017) Aripiprazole lauroxil: pharmacokinetic profile of this long-acting injectable antipsychotic in persons with schizophrenia. J Clin Psychopharmacol 37(3):289PubMedPubMedCentralCrossRef
48.
Zhang H (2004) The optimality of naive Bayes. Aa 1(2):3
49.
Rish I (2001) An empirical study of the naive Bayes classifier. In: IJCAI 2001 workshop on empirical methods in artificial intelligence, vol. 22. pp 41–46
50.
Domingos P, Pazzani M (1997) On the optimality of the simple Bayesian classifier under zero-one loss. Mach Learn 29:103–130CrossRef
51.
Lewis DD (1998) Naive (Bayes) at forty: the independence assumption in information retrieval. In: European conference on machine learning. Springer, pp 4–15
52.
Goodyear K, Haass-Koffler CL, Chavanne D (2018) Opioid use and stigma: the role of gender, language and precipitating events. Drug Alcohol Depend 185:339–346PubMedPubMedCentralCrossRef
53.
Sorsdahl K, Stein DJ, Myers B (2012) Negative attributions towards people with substance use disorders in South Africa: variation across substances and by gender. BMC Psychiatry 12:1–8CrossRef
54.
Corrigan PW, Wassel A (2008) Understanding and influencing the stigma of mental illness. J Psychosoc Nurs Ment Health Serv 46(1):42–48PubMedCrossRef
55.
Tang Q (2017) Discursive constructions of drug issues by Chinese media: problems and solutions. J Commun 5(2):15–21
56.
57.
Luoma JB, Kohlenberg BS, Hayes SC, Bunting K, Rye AK (2008) Reducing self-stigma in substance abuse through acceptance and commitment therapy: model, manual development, and pilot outcomes. Addctn Res Theory 16(2):149–165CrossRef
Metadaten
Titel
Employing Bayesian analysis to establish a cut-off point and assess stigma prevalence in substance use disorder: a comprehensive study of the Chinese version of the Substance Use Stigma Mechanism Scale
verfasst von
Dongfang Wang
Yanan Zhou
Shubao Chen
Qiuxia Wu
Li He
Qianjin Wang
Yuzhu Hao
Yueheng Liu
Pu Peng
Manyun Li
Tieqiao Liu
Yuejiao Ma
Publikationsdatum
27.02.2024
Verlag
Springer Berlin Heidelberg
Erschienen in
Social Psychiatry and Psychiatric Epidemiology / Ausgabe 10/2024
Print ISSN: 0933-7954
Elektronische ISSN: 1433-9285
DOI
https://doi.org/10.1007/s00127-024-02621-5

Weitere Artikel der Ausgabe 10/2024

Perinatal depression and its associated risk factors during the COVID-19 pandemic in low- and middle-income countries: a systematic review and meta-analysis

  • Review

Risk psychosocial factors associated with postpartum depression trajectories from birth to six months

  • Research

Consumers lived experiences and satisfaction with sub-acute mental health residential services

  • Open Access
  • Research

Differential correlates of criticism versus emotional overinvolvement towards patients with schizophrenia living in halfway houses or with their families

  • Open Access
  • Research

Application of cognitive remediation in the world: new experiences from two schizophrenia rehabilitation centers in Togo and Benin

  • Open Access
  • Research

Pregnancy complications and childhood mental health: is the association modified by sex or adverse social circumstances? Findings from the ‘growing up in Ireland’ national infant cohort study

  • Open Access
  • Research

Neu im Fachgebiet Psychiatrie

„Wir wollen die Bedeutung von Gen- und Umwelteinflüssen besser verstehen“

Eine Mutation in einem einzelnen Gen kann bei Mäusen eine Art Bipolarstörung auslösen. PD Dr. Jan Deussing vom Max-Planck-Institut für Psychiatrie in München sieht in solchen Tiermodellen eine Möglichkeit, den Ursachen der Erkrankung auf den Grund zu gehen.

Suizidassistenz erhöht Suizidzahlen: Aktuelle Ergebnisse der geplanten S3-Leitlinie

Erstmals wird in Deutschland eine S3-Leitlinie zum Thema Suizidalität erarbeitet. Ziel ist es, die Versorgung in suizidalen Krisen durch einheitliche Standards zu verbessern. Erste Ergebnisse der bisherigen Leitlinienarbeit wurden auf dem DGPPN-Kongress vorgestellt.

Einer von sieben Frauen macht die Menopause sehr zu schaffen

Von mäßigen bis schweren vasomotorischen Beschwerden sind 14,7% der Frauen in der Postmenopause betroffen. Das haben kanadische Forscherinnen in einer Subgruppenanalyse der WARM-Studie herausgefunden.

Depressive Senioren fahren besonders riskant

Beim Autofahren machen ältere Depressive häufiger eine Vollbremsung, gehen öfter zu schnell in Kurven und halten sich seltener an Tempolimits als Senioren ohne Depression. Offenbar scheint eine Depression eine riskante Fahrweise im Alter zu verstärken.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise